|Mr. Jean-Francois Mouney||Co-Founder & Chairman||285.97k||N/A||1955|
|Mr. M. Pascal Prigent||Chief Exec. Officer||488.02k||N/A||1968|
|Prof. Bart Staels||Co-Founder & Chairman of the Scientific Advisory Board||N/A||N/A||1963|
|Mr. Thomas Baetz||Chief Financial Officer||N/A||N/A||1974|
|Dr. Dean W. Hum||Chief Operating Officer||N/A||N/A||1962|
|Ms. Nathalie Huitorel||Exec. VP & Chief Admin. Officer||N/A||N/A||1961|
|Ms. Naomi Eichenbaum||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Laurent Lannoo||Corp. Sec. & Director of Legal Affairs||N/A||N/A||1970|
|Ms. Stefanie Magner||Chief Compliance Officer & VP of International Legal Affairs||N/A||N/A||1981|
|Mr. Jean-Christophe Marcoux||Chief Strategy Officer||N/A||N/A||1977|
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Genfit SA’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 5; Compensation: 10.